[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343055-105":59,"doc-detail-343055-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","network-meta-analysis-of-combination-strategies-in-metastatic-hormone-sensitive-prostate-cancer","Network meta-analysis of combination strategies in metastatic hormone-sensitive prostate cancer","","Network meta-analysis compared doublet and triplet therapies for efficacy and safety in metastatic hormone-sensitive prostate cancer (mHSPC). PubMed, EMBASE, and the Cochrane Library were searched for eligible randomized controlled trials from inception to October 2023. Interventions included abiraterone, apalutamide, enzalutamide, docetaxel, darolutamide, and androgen deprivation therapy (ADT), assessed across overall survival, progression-free survival, CRPC-free survival, time to symptomatic skeletal event, and toxicity using SUCRA. Ten RCTs were included, with triplet therapy showing potentially enhanced effectiveness and acceptable safety.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/network-meta-analysis-of-combination-strategies-in-metastatic-hormone-sensitive-prostate-cancer/343055/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/network-meta-analysis-of-combination-strategies-in-metastatic-hormone-sensitive-prostate-cancer/343055.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the main aim of the network meta-analysis?","Question",{"text":113,"@type":114},"To compare different doublet and triplet therapies for efficacy and safety in metastatic hormone-sensitive prostate cancer (mHSPC).","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which treatments were included in the analysis?",{"text":118,"@type":114},"Abiraterone, apalutamide, enzalutamide, docetaxel, darolutamide, and androgen deprivation therapy (ADT), administered as doublet or triplet regimens.",{"name":120,"@type":111,"acceptedAnswer":121},"How were preferred therapies identified and what did the results suggest?",{"text":122,"@type":114},"SUCRA was used to rank treatments. Triplet therapy showed potentially enhanced effectiveness than doublet therapy, with acceptable safety concerns, and darolutamide was suggested as a potentially optimal triplet option with docetaxel and ADT.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},343055,1790171424,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Asian Journal of Andrology (2024) 26, 402–408 [www.asiaandro.com](www.asiaandro.com); [https://journals.lww.com/ajandrology](https://journals.lww.com/ajandrology)  \nOpen Access  \nProstate Cancer  \nORIGINAL ARTICLE  \nNetwork meta-analysis of combination strategies in metastatic hormone-sensitive prostate cancer  \nShan-Shan Wang1,2,*, Xiao-Jie Bian1,2,*, Jun-Long Wu1,2, Bei-He Wang1,2, Sheng Zhang1,3, Ding-Wei Ye1,2  \nThis study compared different doublet and triplet therapies for efficacy and safety in metastatic hormone-sensitive prostate cancer (mHSPC) . PubMed, EMBASE, and the Cochrane Library were comprehensively searched for eligible randomized controlled trials (RCTs) published from inception to October 2023. Interventions included abiraterone, apalutamide, enzalutamide, docetaxel, darolutamide, and androgen deprivation therapy (ADT), either as doublet or triplet therapies. The outcomes examined were overall survival (OS), progression-free survival (PFS), castration-resistant prostate cancer (CRPC)-free survival, time to symptomatic skeletal event (SSE), and toxicity. The surface under the cumulative ranking curve (SUCRA) was determined to identify the preferred treatments. Ten RCTs were included. The combination of darolutamide, docetaxel, and ADT had the highest SUCRA of 84.3 for OS, followed by combined abiraterone, docetaxel, and ADT (SUCRA = 71.6) . The highest SUCRAs for PFS were observed for triplet therapies (abiraterone, docetaxel, and ADT [SUCRA = 74.9], followed by enzalutamide, docetaxel, and ADT [SUCRA = 74.3]) and other androgen receptor axis-targeted therapy-based doublet therapies (SUCRAs: 26.5–59.3) . Darolutamide, docetaxel, and ADT had the highest SUCRAs, i.e. , 80.8 and 84.0 regarding CRPC-free survival and time to SSE, respectively. Regarding Grade >3 adverse events (AEs), the SUCRAs of triplet therapies (SUCRAs: 14.8–31.5) were similar to that of docetaxel and ADT (SUCRA = 39.5) . Three studies had a low risk of bias in all categories; the remaining studies had at least an unclear risk of bias in at least one category. Triplet therapy demonstrated potentially enhanced effectiveness than doublet therapy in mHSPC, with acceptable safety concerns. Darolutamide might be the optimal option for triplet therapy in combination with docetaxel and ADT.  \nAsian Journal of Andrology (2024) 26 , 402–408; doi: 10.4103/aja20242; published online: 12 April 2024 Keywords: androgen antagonist; androgen receptor antagonist; docetaxel; meta-analysis; prostatic neoplasm  \nINTRODUCTION  \nProstate cancer (PCa) is the second most common cancer in men worldwide (annual age-standardized incidence of 29.3/100 000 men)1 and the most prevalent malignancy in men in the USA (annual ageadjusted incidence of 109.8/100 000 men) .2,3 Metastatic PCa includes de novo metastatic hormone-sensitive prostate cancer (mHSPC) and cancers progressing during or after androgen deprivation therapy (ADT), referred to as castration-resistant prostate cancer (mCRPC).4 An interval of \u003C12 months between ADT initiation and castration resistance (i.e., progression to mCRPC) is associated with poor prognosis.5 Hence, providing the optimal treatment timely in patients with mHSPC may delay progression to mCRPC and improve prognosis.2,3,6,7  \nAmong common therapeutic regimens for mHSPC, ADT prevents testosterone production and deprives the cancer cells of the inducing effects of testosterone;8 docetaxel prevents mitosis and induces apoptosis,9 and androgen receptor axis-targeted therapies (ARATs) act on different components of the androgen receptor axis.10 According to patient characteristics and prognosis, doublet treatment options for mHSPC include ADT combined with ARATs ( i. e. , abiraterone, apalutamide, or enzalutamide) and ADT combined with docetaxel.2,3,6,7,11,12 In addition, adding abiraterone,13 apalutamide,14 or  \nenzalutamide15 to ADT provides survival benefits to mHSPC cases. Ina network meta-analysis, all combination regimens had better efficac","cbCaibIHiZ3YMjmA","https://ap.wps.com/l/cbCaibIHiZ3YMjmA","pdf",1341498,"English","# Introduction\n# Materials and Methods\n## Search strategy","[{\"question\":\"What was the main aim of the network meta-analysis?\",\"answer\":\"To compare different doublet and triplet therapies for efficacy and safety in metastatic hormone-sensitive prostate cancer (mHSPC).\"},{\"question\":\"Which treatments were included in the analysis?\",\"answer\":\"Abiraterone, apalutamide, enzalutamide, docetaxel, darolutamide, and androgen deprivation therapy (ADT), administered as doublet or triplet regimens.\"},{\"question\":\"How were preferred therapies identified and what did the results suggest?\",\"answer\":\"SUCRA was used to rank treatments. Triplet therapy showed potentially enhanced effectiveness than doublet therapy, with acceptable safety concerns, and darolutamide was suggested as a potentially optimal triplet option with docetaxel and ADT.\"}]","Network meta-analysis of combination strategies in metastatic hormone-sensitive prostate cancer | PDF",1790049619,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/add147936e90ad07b2f1176de2ac142a.webp",983,1287,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d3c1337049442ce698b22163046a8c1c.webp",982,1286,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7953a61c944e61a11b0fc0c2ff490eff.webp",981,1284,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/941adb7b8a413b45af34310653309cd5.webp",980,1283]